GlaxoSmithKline taps Cold Spring Harbor for diabetes R&D

GlaxoSmithKline ($GSK) has reached out to the storied Cold Spring Harbor Laboratory to collaborate on a potential treatment for Type 2 diabetes and obesity, inking a multiyear R&D deal. Under the agreement, the two will work together on small-molecule candidates that block the phosphatase PTP1B in hopes of making the body more receptive to insulin and battling diabetes and obesity. The collaboration, run through GSK's Discovery Partnership with Academia program, is designed to accelerate the company's in-house projects in metabolic disease. More

Suggested Articles

Fifteen of the 22 patients in a gene therapy trial no longer needed transfusions, while the remainder needed fewer transfusions.

Argos Therapeutics is ending its kidney cancer trial and mulling options, including a merger or sale, to stay alive.

CNS Pharma says berubicin is the first anthracycline drug to cross the blood-brain barrier and could transform treatment of the highly invasive brain tumor.